Selección de publicaciones

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Llacer C, Alvarez M, de Luque V, Molina C, Teijeira A, Berraondo P, Melero I. Nature. 2019 May 1. 569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1. IF: 41.577. Q1,D1

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I. Nat Med. 2019 Feb 11. doi: 10.1038/s41591-018-0339-5. IF:32,621. Q1,D1

An RNA toolbox for cancer immunotherapy. Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I. Nat Rev Drug Discovery. 2018 Oct;17(10):751-767. doi: 10.1038/nrd.2018.132. Epub 2018 Sep 7. Review. IF: 50,167. Q1,D1

Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant Semliki Forest Virus-derived vectors fosters dendritic cell-mediated T cell cross-priming. Sanchez-Paulete AR, Teijeira A, Quetglas JI, Rodriguez-Ruiz ME, Sanchez-Arraez A, Labiano S, Etxeberria I, Azpilikueta A, Bolaños E, Ballesteros-Briones MC, Casares N, Quezada SA, Berraondo P, Sancho D, Smerdou C, Melero I. Cancer Reseach. 2018 Oct 8. pii: canres.0933.2018. doi: 10.1158/0008-5472.CAN-18-0933. IF: 9,130. Q1,D1

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I. Ann Oncol. 2018 May 1;29(5):1312-1319. IF: 13,93. Q1,D1

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients. Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Ann Oncol. 2017 Jun 8. doi: 10.1093/annonc/mdx190. IF: 13,93. Q1,D1

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. The Lancet. 2017 Apr 20. pii: S0140-6736(17)31046-2. doi: 10.1016/S0140-6736(17)31046-2. IF: 47,831. Q1,D1

Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolanos E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I. Cancer Res. 2016 Aug 22. pii: canres.0549.2016. IF: 9,122. Q1,D1

Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells. Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, Sancho D, Melero I. Cancer Discov. 2015 Oct 22. pii: CD-15-0510. IF: 20,010. Q1,D1

Evolving synergistic combinations of targeted immunotherapies to combat cancer. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JL, Haanen J. Nat Rev Cancer. 2015 Jul 24;15(8):457-72. doi: 10.1038/nrc3973.  IF: 37,147. Q1,D1


"Los anticuerpos monoclonales inmunoestimulantes son herramientas terapéuticas que suministran instrucciones a las células del sistema inmunitario para erradicar tumores, actúan interfiriendo con receptores inhibidores o estimulando receptores activadores", Dr. Ignacio Melero.

Contacto

Contacto:
Cibeles Pinto
Avda. Pío XII, 55
31008 Pamplona
España

+34 948 194 700 Ext. 4012
mcpinto@unav.es